Your browser doesn't support javascript.
loading
Bayesian response adaptive randomization design with a composite endpoint of mortality and morbidity.
Xu, Zhongying; Ma, Tianzhou; Tang, Lu; Talisa, Victor B; Chang, Chung-Chou H.
  • Xu Z; Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Ma T; Department of Epidemiology and Biostatistics, School of Public Health, University of Maryland, College Park, Maryland, USA.
  • Tang L; Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Talisa VB; Department of Critical Care Medicine, School of Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Chang CH; Department of Biostatistics, School of Public Health, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Stat Med ; 43(6): 1256-1270, 2024 Mar 15.
Article en En | MEDLINE | ID: mdl-38258898
ABSTRACT
Allocating patients to treatment arms during a trial based on the observed responses accumulated up to the decision point, and sequential adaptation of this allocation, could minimize the expected number of failures or maximize total benefits to patients. In this study, we developed a Bayesian response-adaptive randomization (RAR) design targeting the endpoint of organ support-free days (OSFD) for patients admitted to the intensive care units. The OSFD is a mixture of mortality and morbidity assessed by the number of days of free of organ support within a predetermined post-randomization time-window. In the past, researchers treated OSFD as an ordinal outcome variable where the lowest category is death. We propose a novel RAR design for a composite endpoint of mortality and morbidity, for example, OSFD, by using a Bayesian mixture model with a Markov chain Monte Carlo sampling to estimate the posterior probability distribution of OSFD and determine treatment allocation ratios at each interim. Simulations were conducted to compare the performance of our proposed design under various randomization rules and different alpha spending functions. The results show that our RAR design using Bayesian inference allocated more patients to the better performing arm(s) compared to other existing adaptive rules while assuring adequate power and type I error rate control across a range of plausible clinical scenarios.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proyectos de Investigación Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Proyectos de Investigación Tipo de estudio: Clinical_trials / Prognostic_studies Límite: Humans Idioma: En Año: 2024 Tipo del documento: Article